PL2365804T3 - Zmniejszanie obciążenia amyloidem-beta w tkance niemózgowej - Google Patents

Zmniejszanie obciążenia amyloidem-beta w tkance niemózgowej

Info

Publication number
PL2365804T3
PL2365804T3 PL09761084T PL09761084T PL2365804T3 PL 2365804 T3 PL2365804 T3 PL 2365804T3 PL 09761084 T PL09761084 T PL 09761084T PL 09761084 T PL09761084 T PL 09761084T PL 2365804 T3 PL2365804 T3 PL 2365804T3
Authority
PL
Poland
Prior art keywords
amyloid
reduction
brain tissue
beta load
beta
Prior art date
Application number
PL09761084T
Other languages
English (en)
Inventor
J Gregor Sutcliffe
Floyd E Bloom
Brian S Hilbush
Original Assignee
Modgene Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modgene Llc filed Critical Modgene Llc
Publication of PL2365804T3 publication Critical patent/PL2365804T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
PL09761084T 2008-11-13 2009-11-13 Zmniejszanie obciążenia amyloidem-beta w tkance niemózgowej PL2365804T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11445908P 2008-11-13 2008-11-13
US23092609P 2009-08-03 2009-08-03
PCT/US2009/064430 WO2010057020A2 (en) 2008-11-13 2009-11-13 Modification of amyloid-beta load in non-brain tissue
EP09761084.4A EP2365804B1 (en) 2008-11-13 2009-11-13 Reduction of amyloid-beta load in non-brain tissue

Publications (1)

Publication Number Publication Date
PL2365804T3 true PL2365804T3 (pl) 2015-10-30

Family

ID=42165803

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09761084T PL2365804T3 (pl) 2008-11-13 2009-11-13 Zmniejszanie obciążenia amyloidem-beta w tkance niemózgowej

Country Status (13)

Country Link
US (2) US20100120787A1 (pl)
EP (1) EP2365804B1 (pl)
JP (2) JP2012508770A (pl)
CN (1) CN102271669A (pl)
AU (1) AU2009313851A1 (pl)
CA (1) CA2742771A1 (pl)
DK (1) DK2365804T3 (pl)
ES (1) ES2543987T3 (pl)
HU (1) HUE027027T2 (pl)
MX (1) MX2011004891A (pl)
PL (1) PL2365804T3 (pl)
PT (1) PT2365804E (pl)
WO (1) WO2010057020A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
KR20120017469A (ko) * 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
WO2008153959A1 (en) * 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
ES2607794T3 (es) * 2007-06-07 2017-04-04 Intra-Cellular Therapies, Inc. Compuestos heterocíclicos novedosos y usos de los mismos
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
WO2012080703A1 (en) * 2010-12-15 2012-06-21 Cipla Limited Pharmaceutical composition comprising imatinib
HUE041391T2 (hu) 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
MX352749B (es) * 2011-11-01 2017-12-06 Modgene Llc Composiciones y metodos para la reduccion de la carga amiloide-beta.
US20160289762A1 (en) 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
WO2013113012A2 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
US10149855B2 (en) * 2014-02-05 2018-12-11 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN105018484B (zh) * 2015-07-31 2017-10-13 北京泱深生物信息技术有限公司 Crtap基因及其表达产物作为阿尔茨海默病的诊治靶标
CN105651840B (zh) * 2016-04-01 2017-12-26 商丘师范学院 一种检测β‑淀粉样蛋白寡聚体的类免疫电化学传感器及其制备方法
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126451A1 (en) * 1991-12-24 1993-07-08 Brett P. Monia Compositions and methods for modulating .beta.-amyloid
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU702293B2 (en) * 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US7910586B2 (en) * 2002-01-04 2011-03-22 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
AT413944B (de) * 2003-05-27 2006-07-15 Binder Eva Dkfm Verwendung von oxicam-verbindungen
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
EP1940442A4 (en) * 2005-08-04 2009-08-19 Einstein Coll Med Phosphorylation of tau by abl
WO2007103683A2 (en) * 2006-03-01 2007-09-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production
JPWO2007139120A1 (ja) * 2006-05-30 2009-10-08 国立大学法人大阪大学 アミロイドβクリアランス促進剤
DK2142515T3 (da) * 2007-04-18 2014-06-23 Probiodrug Ag Nitrovinyl-diaminderivater som glutaminyl-cyclase-inhibitorer

Also Published As

Publication number Publication date
EP2365804B1 (en) 2015-05-06
MX2011004891A (es) 2011-10-06
CA2742771A1 (en) 2010-05-20
WO2010057020A2 (en) 2010-05-20
WO2010057020A3 (en) 2010-11-25
HK1162150A1 (en) 2012-08-24
AU2009313851A1 (en) 2010-05-20
PT2365804E (pt) 2015-09-16
HUE027027T2 (en) 2016-08-29
EP2365804A2 (en) 2011-09-21
US20100120787A1 (en) 2010-05-13
DK2365804T3 (en) 2015-07-27
JP2012508770A (ja) 2012-04-12
ES2543987T3 (es) 2015-08-26
JP2015172061A (ja) 2015-10-01
US20160287587A1 (en) 2016-10-06
CN102271669A (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
PL2365804T3 (pl) Zmniejszanie obciążenia amyloidem-beta w tkance niemózgowej
IL212856A0 (en) Human antibodies against human tissue factor
IL216128A (en) Antibodies to ngf with increased in vivo stability
AU320819S (en) Surgical spatula
EP2273942A4 (en) FABRIC ANCHOR FOR FIXING FABRIC LAYERS
EP2255730A4 (en) ULTRASOUND
IL208458A0 (en) Compositions and methods for skin care
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
EP2498701A4 (en) COMBATING BONE COMPRESSIONS
GB0800145D0 (en) Skincare treatment
IL213207A0 (en) Dihydroetorphines and their preparation
ZA201102615B (en) Efficient expression of truncated human rnaset2 in e coli
GB0917612D0 (en) In vivo imaging agents
EP2348968A4 (en) METHODS AND ANALYZES FOR ASSESSING HEART RISK AND ISCHEMIA
GB0812080D0 (en) Human propeeled boat
GB0819808D0 (en) Supine stabilizer
BRPI0907738A2 (pt) Liposucção de gordura visceral usando liquefação de tecido
IL211849A (en) שיטוט לא–פולשניות להערכת תגובה ווסומוטרית in vivo
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
ZA201103771B (en) Hypoallergenic dermatological composition
GB0809820D0 (en) Modified tissues
SG10202006468XA (en) Human antibodies against human tissue factor
PH32008000854S1 (en) Tissue
GB0821633D0 (en) Soft tissue anchor
TWM347115U (en) Tableware for healthy living